No Data
No Data
Mindray Healthcare (300760): Steady growth in performance, optimistic about new business expansion and acceleration of overseas layout
Core view The company's annual report and quarterly results are in line with expectations. The impact of increased industry compliance requirements on equipment bidding is expected to gradually weaken, and the medical equipment renewal policy is expected to bring about some incremental demand; after the company also stated that Huitai Healthcare is expected to begin in the second quarter
Express News | Recent Overseas Institutional Research Unit List: Mindray Healthcare ranked first in the survey by 80 overseas institutions
Mindray Healthcare (300760) review: 2023 and 2024Q1 results are in line with expectations, optimistic about the company's long-term steady growth
Investment highlights: 2023 and 2024Q1 results are in line with expectations. The company released its 2023 annual report. In 2023, the company achieved operating income of 34.93 billion yuan, an increase of 15% over the previous year; net profit to mother was 115.8
Mindray Healthcare (300760.SZ): Model of “Made in China” for medical devices
On the eve of the long holiday, the A-share market performed well. Following a single-day northbound capital inflow that hit a record high since the opening of the Mainland Stock Connect on April 26, the three major A-share indices collectively surged in the intraday market on April 29, and the Shanghai Composite Index once again reached 3,100 points, returning to the annual line. Among them, Mindray Healthcare, the leading medical device company that just released its 2023 report and 2024 quarterly report, also rose sharply with an excellent report card, with an intraday increase of more than 6%. The net capital inflow reached 420 million yuan on the same day, and the net purchase of Land Stock Connect reached 227 million yuan, showing impressive performance. Chart 1: Mindray Healthcare's stock price performance Data source: WIND, GEG
Mindray Healthcare (300760): Performance is in line with expectations and is further moving towards a global leader
Event: The company released its 2023 annual report and 2024 quarterly report. Achieved operating income of $34.932 billion (+15.04%) and net profit of $11.582 billion (+20.56%) to mother in 2023
Mindray Healthcare (300760): Performance is in line with expectations, overseas markets accelerate
Summary of the paragraph: In 2023, the company achieved operating income of 34.93 billion yuan (+15.04%, same ratio, same below), achieved net profit attributable to mother of 11.58 billion yuan (+20.6%), and realized net profit deducted from non-mother 114.
No Data